GLP-1 Medications List: Names, Forms and Label Uses
November 1, 2026
Educational only. Not medical advice. Talk to your doctor.
Short answer: As of November 1, 2026, DailyMed carries current US labels for GLP-1 medicines with these active ingredients: semaglutide (Ozempic®, Rybelsus®, Wegovy®), liraglutide (Victoza®, Saxenda® and generics), dulaglutide (Trulicity®), tirzepatide (Mounjaro®, Zepbound®), orforglipron (Foundayo®) and exenatide, plus two pens that pair a long-acting insulin with lixisenatide or liraglutide. They come as weekly shots, daily shots or daily tablets. Each label lists specific uses, mainly type 2 diabetes or weight management, and your prescriber decides which, if any, fits you.
What counts as a GLP-1 medicine?
A GLP-1 medicine acts on the receptor for glucagon-like peptide-1, a hormone the body makes. The labels call these medicines GLP-1 receptor agonists: the Foundayo label, for example, says its medicine “binds to and activates the human GLP-1 receptor.” Tirzepatide (Mounjaro, Zepbound) is usually grouped with them, but its label says it acts on two receptors: “Tirzepatide is a GIP receptor and GLP-1 receptor agonist.” For how the class works, see What is a GLP-1?.
Which GLP-1 medicines have current US labels?
The table lists each product with its label on DailyMed, checked on November 1, 2026. Uses are shortened from Section 1 of each label; strengths and dosing are left to your prescriber.
| Medicine | Active ingredient | How it is taken | Uses listed in Section 1 | Label date |
|---|---|---|---|---|
| Ozempic injection | Semaglutide | Shot under the skin, once weekly | Blood sugar control in adults with type 2 diabetes; lowering the risk of major heart events in adults with type 2 diabetes and heart disease; lowering the risk of kidney decline, kidney failure and heart death in adults with type 2 diabetes and chronic kidney disease | June 1, 2026 |
| Ozempic tablets and Rybelsus | Semaglutide | Tablet, once daily, on an empty stomach | Blood sugar control in adults with type 2 diabetes; lowering the risk of major heart events in adults with type 2 diabetes at high risk | January 30, 2026 |
| Wegovy injection | Semaglutide | Shot under the skin, once weekly | Lowering the risk of major heart events in adults with heart disease and obesity or overweight; weight reduction in adults and in children 12 and older with obesity; a liver condition (MASH) with moderate to advanced fibrosis in adults | June 18, 2026 |
| Wegovy tablets | Semaglutide | Tablet, once daily, on an empty stomach | Lowering the risk of major heart events in adults with heart disease and obesity or overweight; weight reduction in adults | June 18, 2026 |
| Victoza | Liraglutide | Shot under the skin, once daily | Blood sugar control in adults and children 10 and older with type 2 diabetes; lowering the risk of major heart events in adults with type 2 diabetes and heart disease | October 14, 2025 |
| Saxenda | Liraglutide | Shot under the skin, once daily | Weight reduction in adults, and in children 12 and older who weigh more than 132 lbs (60 kg) and have obesity | February 25, 2026 |
| Trulicity | Dulaglutide | Shot under the skin, once weekly | Blood sugar control in adults and children 10 and older with type 2 diabetes; lowering the risk of major heart events in adults with type 2 diabetes and heart disease or several heart risk factors | June 16, 2026 |
| Mounjaro | Tirzepatide | Shot under the skin, once weekly | Blood sugar control in adults and children 10 and older with type 2 diabetes; lowering the risk of major heart events in adults with type 2 diabetes at high risk | August 27, 2026 |
| Zepbound | Tirzepatide | Shot under the skin, once weekly | Weight reduction in adults with obesity, or overweight and a weight-related condition; moderate to severe obstructive sleep apnea in adults with obesity | August 28, 2026 |
| Foundayo | Orforglipron | Tablet, once daily, with or without food | Weight reduction in adults with obesity, or overweight and a weight-related condition | July 29, 2026 |
| Exenatide injection (brand-name and generic versions) | Exenatide | Shot under the skin, twice daily, within the hour before the morning and evening meals | Blood sugar control in adults with type 2 diabetes | May 27, 2026 (generic) |
| Insulin glargine and lixisenatide (combination pen) | Lixisenatide with a long-acting insulin | Shot under the skin, once daily, within the hour before the first meal | Blood sugar control in adults with type 2 diabetes | March 18, 2026 |
| Insulin degludec and liraglutide (combination pen) | Liraglutide with a long-acting insulin | Shot under the skin, once daily, at the same time each day | Blood sugar control in adults with type 2 diabetes | October 14, 2025 |
Wegovy injection’s liver indication is under accelerated approval, which its label says may depend on a confirmatory trial. A DailyMed search on November 1, 2026 returned no current label for once-weekly extended-release exenatide or for lixisenatide on its own; if you used one of those before, ask your pharmacist what is available now.
Which GLP-1 medicines are for type 2 diabetes, and which are for weight?
Three active ingredients are sold under two brand names each, one labeled mainly for type 2 diabetes and one for weight management:
| Active ingredient | Type 2 diabetes label | Weight management label |
|---|---|---|
| Semaglutide | Ozempic (injection and tablets), Rybelsus | Wegovy (injection and tablets) |
| Liraglutide | Victoza | Saxenda |
| Tirzepatide | Mounjaro | Zepbound |
Dulaglutide (Trulicity), exenatide and the two insulin combinations are labeled for type 2 diabetes only. Foundayo is labeled for weight reduction only. For how the paired brands differ, see Ozempic vs Wegovy, Mounjaro vs Zepbound.
Which GLP-1 medicines come as pills?
Three labels cover tablets:
- Wegovy tablets (semaglutide), once daily on an empty stomach with up to 4 ounces of plain water; see Wegovy pill: what the label says.
- Rybelsus and Ozempic tablets (semaglutide), one shared label with the same empty-stomach steps. Ozempic tablets are a newer tablet formulation, and the label says the two “are not substitutable on a mg-to-mg basis,” so any switch goes through your prescriber and pharmacist.
- Foundayo (orforglipron), once daily, with or without food; see Foundayo: what the label says.
For tablets next to the weekly shots, see GLP-1 pills vs shots.
Are there generic GLP-1 medicines?
Yes, for two ingredients. A DailyMed search on November 1, 2026 lists generic liraglutide injection from several manufacturers, with some labels matching the type 2 diabetes use and others the weight management use, and a generic exenatide injection. For semaglutide, tirzepatide and dulaglutide, the same search lists only the Novo Nordisk or Eli Lilly products and repackaged versions of them.
Compounded semaglutide or tirzepatide is not on this list. The FDA says it “does not review compounded drugs for safety, effectiveness or quality before they are marketed,” and advises getting a prescription from your doctor and filling it at a state-licensed pharmacy. Ask your prescriber and pharmacist about what you are taking.
Can you take two GLP-1 medicines together?
The labels advise against it. The Wegovy label says use with “other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.” The Zepbound, Saxenda and Foundayo labels say the same about other GLP-1 receptor agonists, and the Victoza label says not to use it with other liraglutide products. The insulin combination pens contain a GLP-1 medicine too, so they count. Keep a full list of your medicines and show it to every prescriber and pharmacist.
What do the labels have in common?
The thirteen brand and generic labels behind the table all warn about inflammation of the pancreas (acute pancreatitis), severe stomach and bowel side effects, kidney problems from fluid loss, and the risk of food or liquid getting into the lungs during anesthesia or deep sedation. Most also open with a boxed warning about thyroid C-cell tumors seen in rodents. The twice-daily exenatide labels and the insulin glargine and lixisenatide label do not carry that boxed warning. For the side effect figures, see GLP-1 side effects, and for how long each medicine stays in the body, see how long GLP-1 medicines stay in your system.
How can you keep track?
If you switch between products, or move from a daily to a weekly medicine, the names and schedules can blur. Writing down which medicine, which form and which day helps at appointments. Weeko, a shot tracker coming to iPhone and Android, is being built around this kind of simple log. It is a logbook, not medical guidance.
When to call your doctor
Ask your prescriber which medicine on this list, if any, fits your situation, and before switching between products, forms or brands. Tell every prescriber and pharmacist about all your medicines, including insulin or a sulfonylurea, and about any planned surgery or procedure with anesthesia or deep sedation. The labels say to call right away for severe stomach pain that will not go away, with or without vomiting, and to get emergency help for signs of a serious allergic reaction. Tell your prescriber about a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. If you take too much of any medicine, call Poison Help at 1-800-222-1222.
Related guides
Sources
- Ozempic (semaglutide) injection prescribing information, DailyMed
- Rybelsus and Ozempic (semaglutide) tablets prescribing information, DailyMed
- Wegovy (semaglutide) injection and tablets prescribing information, DailyMed
- Victoza (liraglutide) injection prescribing information, DailyMed
- Saxenda (liraglutide) injection prescribing information, DailyMed
- Trulicity (dulaglutide) injection prescribing information, DailyMed
- Mounjaro (tirzepatide) injection prescribing information, DailyMed
- Zepbound (tirzepatide) injection prescribing information, DailyMed
- Foundayo (orforglipron) tablets prescribing information, DailyMed
- Exenatide injection (generic) prescribing information, DailyMed
- Insulin glargine and lixisenatide injection prescribing information, DailyMed
- Insulin degludec and liraglutide injection prescribing information, DailyMed
- Liraglutide injection (generic, weight management) prescribing information, DailyMed
- Liraglutide injection (generic, type 2 diabetes) prescribing information, DailyMed
- FDA's concerns with unapproved GLP-1 drugs used for weight loss, FDA
Ozempic®, Wegovy®, Rybelsus®, Saxenda®, Victoza® are trademarks of Novo Nordisk A/S; Mounjaro®, Zepbound®, Trulicity®, Foundayo® are trademarks of Eli Lilly and Company. Weeko is not affiliated with or endorsed by these companies.